The three-year agreement will afford the university with $9.5 million in support and spans multiple disciplines.
Pfizer and the University of California, San Francisco (UCSF) are working together on basic research to ultimately advance drug discovery. UCSF will recieve $9.5 million over three years in research funding and other support.
The agreement establishes a university team to help identify areas of mutual interest and facilitate project management. It will also encourage partnerships between Pfizer and UCSF’s unit of QB3, the multicampus California Institute for Quantitative Biosciences, headquartered at UCSF.
Pfizer’s Biotherapeutics and Bioinnovation Center (BBC), will lead the collaboration, and QB3 will manage the work. Participation will be open to all UCSF scientists as well as those from UC Berkeley and UC Santa Cruz.
Unlike most industry/academia collaborations where the participating parties are looking for a specific line of research, this new and experimental venture assembles teams of Pfizer and university scientists to work on projects in health-related areas of mutual interest, the company points out.
